Format

Send to

Choose Destination
Cancer Biol Ther. 2015;16(6):821-33. doi: 10.1080/15384047.2015.1040961. Epub 2015 Apr 21.

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.

Author information

1
a The Ohio State University Wexner Medical Center ; Department of Neurological Surgery ; Columbus , OH USA.

Abstract

Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase that plays a significant role in mitotic progression and cellular responses to DNA damage. While traditionally viewed as a tumor suppressor, inhibition of PP2A has recently come to attention as a novel therapeutic means of driving senescent cancer cells into mitosis and promoting cell death via mitotic catastrophe. These findings have been corroborated in numerous studies utilizing naturally produced compounds that selectively inhibit PP2A. To overcome the known human toxicities associated with these compounds, a water-soluble small molecule inhibitor, LB100, was recently developed to competitively inhibit the PP2A protein. This review summarizes the pre-clinical studies to date that have demonstrated the anti-cancer activity of LB100 via its chemo- and radio-sensitizing properties. These studies demonstrate the tremendous therapeutic potential of LB100 in a variety of cancer types. The results of an ongoing phase 1 trial are eagerly anticipated.

KEYWORDS:

ABC, ATP-binding cassette.; APC, adenomatous polyposis coli; ARPP19, cyclic AMP-regulated phosphoprotein 19; ATM, ataxia-telangiectasia mutated; CIP2A, cancerous inhibitor of PP2A; CNTF, ciliary neurotrophic factor; DISC, death-inducing signaling complex; DVL, dishevelled; ENSA, α-endosulphine; GBM, glioblastoma; GFAP, glial fibrillary acidic protein; HCC, hepatocellular carcinoma; HDACs, histone deacetylase complexes; HIF-1a, hypoxia-inducible factor-1a; HRR, homologous recombination repair; MDM2, mouse double minute 2 homolog; MRI, magnetic resonance imaging; NPC, nasopharyngeal carcinoma; PP2A, protein phosphatase 2A; Plk1, polo-like kinase 1; TCTP, translationally-controlled tumor protein; TMZ, temozolomide; TRAIL, TNF-related apoptosis-inducing ligand; VEGF, vascular endothelial growth factor; cell cycle; chemosensitization; mitotic catastrophe; protein phosphatase 2A; radiosensitizationreview; small molecule inhibitor

PMID:
25897893
PMCID:
PMC4623051
DOI:
10.1080/15384047.2015.1040961
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center